Compare AbbVie Inc (ABBV) vs Beyond Meat Inc (BYND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Beyond Meat Inc — how do they compare? AbbVie Inc trades at $250.35 (market cap $438.19B), while Beyond Meat Inc trades at $0.42 (market cap $268.23M). The key difference: AbbVie Inc is far larger — about 1633.6× Beyond Meat Inc's market cap, and AbbVie Inc pays a 2.79% dividend while Beyond Meat Inc pays none. Which is the better fit depends on your goals.
| ABBV | BYND | |
|---|---|---|
Market Cap | $438.19B | $268.23M |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $3.62 |
52-Week Low | $197.38 | $0.42 |
Enterprise Value | $502.45B | $508.51M |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
BYND trades at $0.5377, up 1.93% today, but remains in a deep bearish technical trend with weak sentiment. The company reported a surprising net income of $178M in 2025 after years of losses, though revenue continues to decline. Recent Q2 2026 earnings showed a smaller loss than expected, with management focusing on international expansion and new product launches like Beyond Steak Filet to drive a turnaround.
The outlook remains challenging with declining revenue, negative operating cash flow, and heavy reliance on financing. Analyst consensus is overwhelmingly bearish with 57% sell ratings. Key risks include execution of the turnaround strategy, intense competition, and persistent cash burn. The stock presents high risk with potential reward contingent on successful business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
